Effects of glucagon on insulin secretion and glucose metabolism in people without diabetes
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
This study is testing how glucagon affects insulin and blood sugar levels in people who have normal or slightly high fasting glucose to better understand how to manage blood sugar.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 25 Years to 65 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT06424106 on ClinicalTrials.gov |
What this trial studies
This study investigates how glucagon and insulin interact to regulate fasting glucose levels in individuals with normal or impaired fasting glucose. It aims to understand the mechanisms behind fasting hyperglycemia, which is a significant contributor to complications in type 2 diabetes. The research will involve administering glucagon and glucose to assess their effects on insulin secretion and glucose metabolism. By exploring these interactions, the study seeks to fill gaps in knowledge regarding fasting glucose regulation in health and prediabetes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance.
Not a fit: Patients with an HbA1c less than 6.5% or those currently using glucose-lowering agents will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of fasting glucose levels, potentially reducing the risk of developing type 2 diabetes.
How similar studies have performed: While the specific interactions being studied may not have been extensively tested, the investigation into glucagon's role in glucose metabolism is a relevant area of research with potential for significant findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance Exclusion Criteria: * HbA1c less than 6.5% * Use of any glucose-lowering agents including metformin or sulfonylureas. * For female subjects: positive pregnancy test at the time of enrollment or study * History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. * Active systemic illness or malignancy. * Symptomatic macrovascular or microvascular disease.
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Adrian Vella, MD — Mayo Clinic
- Study coordinator: Kim Osmundson, CCRP
- Email: Osmundson.Kimberly@mayo.edu
- Phone: 507-255-0907
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.